Investing.com - Financial Markets Worldwide

Crispr Therapeutics files to offer up to $600 million in new common shares

Published 15/10/2025, 21:28
Crispr Therapeutics files to offer up to $600 million in new common shares
CRSP
0.60%

CRISPR Therapeutics AG (NASDAQ:CRSP) announced Wednesday that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission to offer and sell, from time to time, additional common shares with an aggregate offering price of up to $600 million.

According to the company’s statement in the SEC filing, the shares will be sold through Jefferies LLC acting as sales agent under an existing Open Market Sale Agreement. The offering will be conducted at the company’s discretion, and the shares will be issued pursuant to a previously filed shelf registration statement on Form S-3ASR (File No. 333-281262), which became effective on August 5, 2024.

The common shares being offered have a nominal value of CHF 0.03 per share and are listed on The Nasdaq Global Market under the trading symbol CRSP.

The legal opinion regarding the validity of the shares to be issued in the offering has been provided by Walder Wyss AG, as noted in the exhibits attached to the filing.

The company stated that this current report does not constitute an offer to sell or a solicitation of an offer to buy the securities in any jurisdiction where such an offer or sale would be unlawful prior to registration or qualification under applicable securities laws.

This information is based on a statement made in a press release filed with the SEC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.